Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AGI-134||AGI 134|AGI134|aGal AGI-134|Alpha-Gal AGI-134||AGI-134 is a synthetic glycolipid consisting of an alpha-Gal trisaccharide and lipid tail, which potentially induces cytotoxicity and leads to tumor regression (PMID: 31889898).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung carcinoma||not applicable||AGI-134||Preclinical - Cell culture||Actionable||In a preclinical study, AGI-134 treatment induced cell death of lung carcinoma cells in the presence of normal human serum in culture and induced phagocytosis when co-cultured with human macrophages (PMID: 31889898).||31889898|
|Unknown unknown||colon adenocarcinoma||not applicable||AGI-134||Preclinical - Cell culture||Actionable||In a preclinical study, AGI-134 treatment induced cell death of colon adenocarcinoma cells in the presence of normal human serum in culture (PMID: 31889898).||31889898|
|Unknown unknown||melanoma||not applicable||AGI-134||Preclinical||Actionable||In a preclinical study, AGI-134 treatment induced tumor regression, reduced formation of secondary lesions and increased survival in mouse models of melanoma (PMID: 31889898).||31889898|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03593226||Phase Ib/II||AGI-134||Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour||Recruiting|